Results 51 to 60 of about 9,592 (218)

Subventricular spread of diffuse intrinsic pontine glioma [PDF]

Acta Neuropathologica, 2014
Diffuse intrinsic pontine glioma (DIPG) is the second most common malignant pediatric brain tumor and the leading cause of brain tumor death in childhood [1]. 80 % of DIPG tumors exhibit a specific mutation (H3K27M) in the genes encoding histone 3.1 or 3.3 [2, 3].
Caretti, V., Bugiani, M., Freret, M., Schellen, P., Jansen, M., Vuurden, D. van, Kaspers, G., Fisher, P.G., Hulleman, E., Wesseling, P., Vogel, H., Monje, M.   +11 more
openaire   +6 more sources

Diffuse Intrinsic Pontine Glioma

, 2015
Diffuse intrinsic pontine gliomas (DIPGs) are almost uniformly fatal, predominantly affect children, and are the most common brainstem tumors of childhood. DIPG is diagnosed based on characteristic magnetic resonance imaging (MRI) findings in a child with typical clinical features, and routine biopsy for tissue diagnosis is not currently part of the ...
Magimairajan Issai Vanan, Vivek Mehta, David D. Eisenstat   +2 more
openaire   +3 more sources

ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis

Nature Communications, 2019
ACVR1 and H3.1K27M mutations co-occur in diffuse intrinsic pontine glioma. Here, the authors generate a mouse model that recapitulates these genetic lesions and show, using genetic and pharmacological approaches, that the bone morphogenetic protein ...
Christine M. Hoeman, Francisco J. Cordero, Guo Hu, Katie Misuraca, Megan M. Romero, Herminio J. Cardona, Javad Nazarian, Rintaro Hashizume, Roger McLendon, Paul Yu, Daniele Procissi, Samantha Gadd, Oren J. Becher   +12 more
doaj   +1 more source

Signal Transduction in Diffuse Intrinsic Pontine Glioma [PDF]

PROTEOMICS, 2019
Abstract Diffuse intrinsic pontine glioma (DIPG) is an untreatable, heterogeneous high‐grade glioma (HGG) of the brainstem. This highly aggressive cancer affects mostly young children and is uniformly fatal. Genomic studies show that DIPG is driven by somatic mutations to histone H3, either H3.1 or H3.3 variants (
Ryan J. Duchatel, Evangeline R. Jackson, Frank Alvaro, Brett Nixon, Hubert Hondermarck, Matthew D. Dun   +5 more
openaire   +2 more sources

Potential New Therapies for Pediatric Diffuse Intrinsic Pontine Glioma

Frontiers in Pharmacology, 2017
Diffuse intrinsic pontine glioma (DIPG) is an extensively invasive malignancy with infiltration into other regions of the brainstem. Although large numbers of specific targeted therapies have been tested, no significant progress has been made in treating
Wenyong Long, Yang Yi, Yang Yi, Shen Chen, Shen Chen, Qi Cao, Wei Zhao, Wei Zhao, Qing Liu   +8 more
doaj   +1 more source

Diffuse intrinsic pontine glioma: Insights into oncogenesis and opportunities for targeted therapy

Pediatric Hematology Oncology Journal, 2023
Diffuse intrinsic pontine glioma (DIPG) is a lethal brainstem tumor that most commonly occurs in young children between the ages of five and ten. DIPG is the leading cause of brain tumor-related death in childhood, with most patients succumbing to the ...
Andrew Groves, Pratiti Bandopadhayay, Tabitha M. Cooney   +2 more
doaj   +1 more source

Pax3 expression enhances PDGF-B-induced brainstem gliomagenesis and characterizes a subset of brainstem glioma [PDF]

, 2014
High-grade Brainstem Glioma (BSG), also known as Diffuse Intrinsic Pontine Glioma (DIPG), is an incurable pediatric brain cancer. Increasing evidence supports the existence of regional differences in gliomagenesis such that BSG is considered a distinct ...
Baker, Suzanne J., Barton, Kelly L., Becher, Oren J., Chung, Alexander, Conway, Simon J., Corcoran, David L., Diaz, Alexander K., Misuraca, Katherine L.   +7 more
core   +3 more sources

The neurovascular unit in diffuse intrinsic pontine gliomas

Free neuropathology, 2021
Free Neuropathology, Bd. 2 (2021)
Fatma E. El-Khouly, Rianne Haumann, Marjolein Breur, Sophie E.M. Veldhuijzen van Zanten, Gertjan J.L. Kaspers, N. Harry Hendrikse, Esther Hulleman, Dannis G. van Vuurden, Marianna Bugiani   +8 more
openaire   +3 more sources

Molecular, pathological, radiological, and immune profiling of non-brainstem pediatric high-grade glioma from the HERBY phase II randomized trial [PDF]

, 2018
The HERBY trial was a phase II open-label, randomized, multicenter trial evaluating bevacizumab (BEV) in addition to temozolomide/radiotherapy in patients with newly diagnosed non-brainstem high-grade glioma (HGG) between the ages of 3 and 18 years.
Brouwer-Visser, Jurriaan, Burford, Anna, Capper, David, Figarella-Branger, Dominique, Garcia, Josep, Garrè, Maria Luisa, Giangaspero, Felice, Grill, Jacques, Haberler, Christine, Izquierdo, Elisa, Jacques, Thomas S., Jaspan, Tim, Jones, Chris, Jones, David T.W., Mackay, Alan, Massimino, Maura, Molinari, Valeria, Morgan, Paul S., Pfister, Stefan M., Pietsch, Torsten, Raman, Pichai, Resnick, Adam C., Rodriguez, Daniel, Smith, Helen, Tam, Rachel, Thakur, Meghna Das, Varlet, Pascale, Varlet, Pascle, Vassal, Gilles, Waanders, Angela J., Würdinger, Thomas   +30 more
core   +7 more sources

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source